Renibus Announces Leadership Transition
Renibus Announces Leadership Transition Jeffrey Keyser, RPh, [...]
Renibus Therapeutics to Present at the Evercore ISI 2024 Emerging Biotech Conference
Renibus Therapeutics to Present at the Evercore ISI 2024 [...]
Renibus Therapeutics Announces Presentation at Oppenheimer 34th Annual Healthcare Conference
Renibus Therapeutics Announces Presentation at Oppenheimer 34th Annual Healthcare [...]
Renibus Announces Publication of Results from Phase 2 Study Evaluating RBT-1 as a Pre-Conditioning Agent to Reduce Post-Operative Complications Following Cardiothoracic Surgery
Renibus Announces Publication of Results from Phase 2 Study [...]
Renibus Announces First Patient Enrolled in PROTECT Phase 3 Study of RBT-1 to Reduce Post-operative Complications After Cardiothoracic Surgery
Renibus Announces First Patient Enrolled in PROTECT Phase 3 [...]
Renibus Therapeutics Announces Participation at Upcoming Investor Conferences
Renibus Therapeutics Announces Participation at Upcoming Investor Conferences SOUTHLAKE, [...]
Renibus Therapeutics Announces Final Close of Upsized Series B Financing, Bringing Total Round to $72 Million
Renibus Therapeutics Announces Final Close of Upsized Series B [...]
Renibus Presents Phase 2 Results on RBT-1, a First-in-Class Preconditioning Agent, at the American Society for Enhanced Recovery and Perioperative Medicine (ASER PM) 2023 Meeting
Renibus Presents Phase 2 Results on RBT-1, a First-in-Class [...]
Renibus Therapeutics Announces $47 Million Financing to Advance Lead Program RBT-1 Through Pivotal Phase 3 Trial
Renibus Therapeutics Announces $47 Million Financing to Advance Lead [...]
Renibus Therapeutics Announces Breakthrough Therapy Designation from US FDA for RBT-1 for the Reduction in Risk of Post-Operative Complications in Patients Undergoing Cardiothoracic Surgery
Renibus Therapeutics Announces Breakthrough Therapy Designation from US FDA for [...]